6 results on '"Milik, Sandra N."'
Search Results
2. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.
- Author
-
Milik, Sandra N., Abdel-Aziz, Amal Kamal, Lasheen, Deena S., Serya, Rabah A.T., Minucci, Saverio, and Abouzid, Khaled A.M.
- Subjects
- *
EPIDERMAL growth factor receptors , *PYRIMIDINES , *LAPATINIB , *CANCER cells , *CANCER treatment , *CANCER invasiveness - Abstract
In light of the emergence of resistance against the currently available EGFR inhibitors, our study focuses on tackling this problem through the development of dual EGFR/HER2 inhibitors with improved enzymatic affinities. Guided by the binding mode of the marketed dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors based on the 6-phenylthieno[2,3- d ]pyrimidine as a core scaffold and hinge binder. After two cycles of screening aiming to identify the optimum aniline headgroup and solubilizing group, we eventually identified 27b as a dual EGFR/HER2 inhibitor with IC 50 values of 91.7 nM and 1.2 μM, respectively. Notably, 27b dramatically reduced the viability of various patient-derived cancer cells preferentially overexpressing EGFR/HER2 (A431, MDA-MBA-361 and SKBr3 with IC 50 values of 1.45, 3.5 and 4.83 μM, respectively). Additionally, 27b efficiently thwarted the proliferation of lapatinib-resistant human non-small lung carcinoma (NCI-H1975) cells, harboring T790 M mutation, with IC 50 of 4.2 μM. Consistently, 27b significantly blocked EGF-induced EGFR activation and inactivated its downstream AKT/mTOR/S6 signalling pathway triggering apoptotic cell death in NCI-H1975 cells. The present study presents a promising candidate for further design and development of novel EGFR/HER2 inhibitors capable of overcoming EGFR TKIs resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
- Author
-
Milik, Sandra N., Lasheen, Deena S., Serya, Rabah A.T., and Abouzid, Khaled A.M.
- Subjects
- *
EPIDERMAL growth factor receptors , *DRUG design , *DRUG approval , *DRUG resistance , *CANCER treatment , *GENETIC mutation - Abstract
Epidermal Growth Factor Receptor (EGFR) stands out as a key player in the development of many cancers. Its dysregulation is associated with a vast number of tumors such as non-small-cell lung cancer, colon cancer, head-and-neck cancer, breast and ovarian cancer. Being implicated in the development of a number of the most lethal cancers worldwide, EGFR has long been considered as a focal target for cancer therapies, ever since the FDA approval of “Gefitinib” in 2003 and up to the last FDA approved small molecule EGFR kinase inhibitor “Osimertinib” in 2015. Studies are still going on to find more efficient EGFR inhibitors due to the continuous emergence of resistance to the current inhibitors. Cancerous cells resist EGFR tyrosine kinase inhibitors (TKIs) through various mechanisms, the most commonly reported ones are the T790M mutation and HER2 amplification. Therefore, tackling EGFR TKIs-resistant tumors through a multi-targeting approach comprising a dual EGFR/HER2 inhibitor that is also capable of inhibiting the mutant T790M EGFR is anticipated to overcome drug resistance. In this review, we will survey the structural aspects of EGFR family and the structure-activity relationship of representative dual EGFR/HER2 inhibitors. To follow, we will discuss the structural aspects of the mutation-driven resistance and various design strategies to overcome it. Finally, we will review the SAR of exemplary irreversible dual EGFR/HER2 inhibitors that can overcome the mutation-driven resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against Gram-negative bacteria.
- Author
-
Dokla, Eman M.E., Abutaleb, Nader S., Milik, Sandra N., Kandil, Ezzat A.E.A., Qassem, Omar M., Elgammal, Yehia, Nasr, Maha, McPhillie, Martin J., Abouzid, Khaled A.M., Seleem, Mohamed N., Imming, Peter, and Adel, Mai
- Subjects
- *
BENZIMIDAZOLES , *GRAM-negative bacteria , *ANTIBACTERIAL agents , *ANTI-infective agents , *COLISTIN , *GRAM-negative bacterial diseases , *ESCHERICHIA coli , *DRUG resistance in bacteria - Abstract
Antibiotic-resistant bacteria represent a serious threat to modern medicine and human life. Only a minority of antibacterial agents are active against Gram-negative bacteria. Hence, the development of novel antimicrobial agents will always be a vital need. In an effort to discover new therapeutics against Gram-negative bacteria, we previously reported a structure-activity-relationship (SAR) study on 1,2-disubstituted benzimidazole derivatives. Compound III showed a potent activity against tolC -mutant Escherichia coli with an MIC value of 2 μg/mL, representing a promising lead for further optimization. Building upon this study, herein, 49 novel benzimidazole compounds were synthesized to investigate their antibacterial activity against Gram-negative bacteria. Our design focused on three main goals, to address the low permeability of our compounds and improve their cellular accumulation, to expand the SAR study to the unexplored ring C, and to optimize the lead compound (III) by modification of the methanesulfonamide moiety. Compounds (25a-d , 25f-h , 25k , 25l , 25p , 25r , 25s , and 26b) exhibited potent activity against tolC -mutant E. coli with MIC values ranging from 0.125 to 4 μg/mL, with compound 25d displaying the highest potency among the tested compounds with an MIC value of 0.125 μg/mL. As its predecessor, III , compound 25d exhibited an excellent safety profile without any significant cytotoxicity to mammalian cells. Time-kill kinetics assay indicated that 25d exhibited a bacteriostatic activity and significantly reduced E. coli JW55031 burden as compared to DMSO. Additionally, combination of 25d with colistin partially restored its antibacterial activity against Gram-negative bacterial strains (MIC values ranging from 4 to 16 μg/mL against E. coli BW25113, K. pneumoniae , A. baumannii , and P. aeruginosa). Furthermore, formulation of III and 25d as lipidic nanoparticles (nanocapsules) resulted in moderate enhancement of their antibacterial activity against Gram-negative bacterial strains (A. Baumannii, N. gonorrhoeae) and compound 25d demonstrated superior activity to the lead compound III. These findings establish compound 25d as a promising candidate for treatment of Gram-negative bacterial infections and emphasize the potential of nano-formulations in overcoming poor cellular accumulation in Gram-negative bacteria where further optimization and investigation are warranted to improve the potency and broaden the spectrum of our compounds. [Display omitted] • An extensive SAR study was established for the lead compound III. • Compound 25d showed potent activity against tolC-mutant E. coli. • 25d is a bacteriostatic agent with excellent safety profile. • Combination of 25d with colistin manifested synergistic activity against Gram-negative bacteria. • 25d nanocapsule formulation improved its activity against some Gram-negative wild strains. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
- Author
-
Dokla, Eman M.E., Abdel-Aziz, Amal Kamal, Milik, Sandra N., McPhillie, Martin J., Minucci, Saverio, and Abouzid, Khaled A.M.
- Subjects
- *
ACUTE myeloid leukemia , *CELL death , *WESTERN immunoblotting , *PROTEIN-tyrosine kinases , *SMALL molecules , *CELL cycle - Abstract
[Display omitted] • A benzimidazole derivative with nanomolar activity against FLT3 and TrKA kinase. • 4ACP was identified via scaffold hopping & structural simplification of quizartinib. • 4ACP prompted apoptotic and necrotic cell death and G0/G1 cell cycle arrest. • 4ACP exhibited selective antiproliferative profile and low toxicity in normal cells. • 4ACP represents a novel FLT3/TrKA dual kinase inhibitor for targeted therapy of AML. FMS-like tyrosine kinase 3 (FLT3) enzyme overexpression and mutations are the most common molecular abnormalities associated with acute myeloid leukemia (AML). In addition, recent studies investigated the role of tropomyosin receptor kinase A (TrKA) enzyme fusions in promoting AML growth and survival. Based on these premises, targeting both kinases using dual inhibitors would constitute a promising therapeutic approach to target resistant AML. Guided by ligand-based design and structure simplification of the FLT3 inhibitor, quizartinib, we developed a benzimidazole-based small molecule, 4ACP , that exhibited nanomolar activity against wild-type FLT3, FLT3-Internal tandem duplications (FLT3-ITD), and FLT3-D835Y (FLT3-TKD) mutation (IC 50 = 43.8, 97.2, and 92.5 nM respectively). Additionally, 4ACP demonstrated potent activity against colon cancer KM12 cell line (IC 50 = 358 nM) and subsequent mechanistic deconvolution identified TrKA enzyme as a second plausible target (IC 50 = 23.6 nM) for our compound. 4ACP manifested preferential antiproliferative activity against FLT3-ITD positive AML cell lines (MV4-11 IC 50 = 38.8 ± 10.7 nM and MOLM-13 IC 50 = 54.9 ± 4.1 nM), while lacking activity against FLT3-ITD negative AML cell lines. Western blot analysis confirmed 4ACP ability to downregulate ERK1/2 and mTOR signaling downstream of FLT3-ITD in AML cells. Furthermore, 4ACP prompted apoptotic and necrotic cell death and G0/G1 cell cycle arrest as indicated by cell cycle analysis. 4ACP did not show cytotoxic effects on normal BNL and H9c2 cells and demonstrated decreased activity against c-Kit enzyme, hence, indicating lower probability of synthetic lethal toxicity and a relatively safer profile. In light of these data, 4ACP represents a novel FLT3/TrKA dual kinase inhibitor for targeted therapy of AML. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria.
- Author
-
Dokla, Eman M.E., Abutaleb, Nader S., Milik, Sandra N., Li, Daoyi, El-Baz, Karim, Shalaby, Menna-Allah W., Al-Karaki, Rawan, Nasr, Maha, Klein, Christian D., Abouzid, Khaled A.M., and Seleem, Mohamed N.
- Subjects
- *
GRAM-negative bacteria , *ANTI-infective agents , *BENZIMIDAZOLES , *COLISTIN , *ANTIBACTERIAL agents , *BENZIMIDAZOLE derivatives , *CELL lines - Abstract
Gram-negative bacteria pose a distinctive risk worldwide, especially with the evolution of major resistance to carbapenems, fluoroquinolones and colistin. Therefore, development of new antibacterial agents to target Gram-negative infections is of utmost importance. Using phenotypic screening, we synthesized and tested thirty-one benzimidazole derivatives against E. coli JW55031 (TolC mutant strain). Compound 6c showed potent activity with MIC value of 2 μg/ml, however, it lacked activity against several Gram-negative microbes with intact efflux systems, including E. coli BW25113 (wild-type strain). Combination of 6c with colistin partially restored its antibacterial activity against wild strains (MIC range, 8–16 μg/ml against E. coli , K. pneumoniae , A. baumannii , and P. aeruginosa). 6c exhibited no cytotoxicity against two mammalian cell lines. Therefore, compound 6c represents a promising lead for further optimization to overcome Gram-negative resistance alone or in combination therapy. Image 1 • Benzimidazole derivative, 6c is a promising lead to target Gram-negative bacteria. • Compound 6c shows potent activity against TolC mutant E. coli. • 6c and colistin manifest synergistic activity against Gram-negative bacteria. • Compound 6c shows no cytotoxicity on mammalian cell lines. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.